Clinical Protocol and Data Management (CPDM) PROJECT SUMMARY The Clinical Protocol and Data Management component of the Dan L Duncan Cancer Center (DLDCC) includes the Clinical Trials Support Unit (CTSU) and the Data Review and Safety Monitoring Committees. The CTSU provides central management, research support and oversight functions for the conduct of cancer- related clinical trials at all ambulatory care centers and hospitals that are part of the DLDCC. CTSU services are available to all members of the DLDCC engaged in clinical research. The major functions of the CTSU are to provide: 1) Assistance with regulatory and administrative matters relating to clinical research and trials, including IRB compliance and approval, ongoing amendments and renewal, external agency compliance (such as the FDA), maintenance of regulatory files, 2) Clinical trials informatics expertise, especially maintaining an electronic database of cancer related clinical protocols, patient registry and clinical data, and monitoring and reporting on accrual, 3) Quality assurance/ Quality Control auditing and personnel training to ensure that the research team is trained in best practices in clinical research, and 4) Research nursing/clinical trials management especially for less experienced investigators. In the most recent year 07/01/2013 ? 06/30/2014 the CTSU supported 170 interventional trials including 59 investigator- initiated studies, 31 of which are conducted under IND and three under an IDE. The Data Review and Safety Monitoring Committees are separate from the operational aspect of clinical trials managed by the CTSU and function to ensure the safety of participants, the validity of data, and the appropriate termination of studies in the event that undue risks have been uncovered, or it appears that trials cannot be conducted successfully. The DLDCC patient safety officer ensures that all data monitoring for Cancer Center trials is conducted in accordance with the approved monitoring plan. Relevance The Clinical Protocol and Data Management component of the Dan L Duncan Cancer Center is committed to providing an effective and efficient infrastructure to support the clinical research efforts of the Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA125123-09
Application #
8934799
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
9
Fiscal Year
2015
Total Cost
$176,586
Indirect Cost
$66,317
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Kundu, Samrat T; Grzeskowiak, Caitlin L; Fradette, Jared J et al. (2018) TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins. Nat Commun 9:2731
Kim, Myunghoo; Galan, Carolina; Hill, Andrea A et al. (2018) Critical Role for the Microbiota in CX3CR1+ Intestinal Mononuclear Phagocyte Regulation of Intestinal T Cell Responses. Immunity 49:151-163.e5
Jeong, Mira; Park, Hyun Jung; Celik, Hamza et al. (2018) Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo. Cell Rep 23:1-10
Morriss, Ginny R; Rajapakshe, Kimal; Huang, Shixia et al. (2018) Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1. Hum Mol Genet 27:2789-2804
Lanza, Denise G; Gaspero, Angelina; Lorenzo, Isabel et al. (2018) Comparative analysis of single-stranded DNA donors to generate conditional null mouse alleles. BMC Biol 16:69
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Boudreaux, Seth P; Duren, Ryan P; Call, Steven G et al. (2018) Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. Leukemia :
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Johnston, A N; Bu, W; Hein, S et al. (2018) Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res 20:42

Showing the most recent 10 out of 991 publications